Tenaya Therapeutics (TNYA) Capital Expenditures (2020 - 2026)
Tenaya Therapeutics' quarterly Capital Expenditures came in at $100000.0 in Q1 2026, down 27.54% year-on-year from $138000.0 in Q1 2025, and up 120.37% quarter-over-quarter from -$491000.0 in Q4 2025.
Tenaya Therapeutics has reported Capital Expenditures for 7 years, with the latest figure at $100000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 27.54% year-over-year to $100000.0; the trailing twelve-month figure through Mar 2026 stood at $22000.0 (down 95.5% YoY), and the FY2025 full-year result was $60000.0, down 83.24% from the prior year.
- Capital Expenditures for Q1 2026 stood at $100000.0, up from -$491000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $20.4 million in Q4 2022, with the low at -$2.8 million in Q3 2022.
- Average Capital Expenditures over 5 years is $1.3 million, with a median of $91000.0 recorded in 2024.
- Year-over-year, Capital Expenditures plunged 671.67% in 2024 and surged 1871.43% in 2025.
- Tracing TNYA's Capital Expenditures over 5 years: stood at $20.4 million in 2022, then sank by 100.29% to -$60000.0 in 2023, then sank by 671.67% to -$463000.0 in 2024, then declined by 6.05% to -$491000.0 in 2025, then surged by 120.37% to $100000.0 in 2026.
- The last three Capital Expenditures figures came in at $100000.0 (Q1 2026), -$491000.0 (Q4 2025), and $544000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Tenaya Therapeutics | 193.57 Mn | 193.57 Mn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | -491,000.00 |
| Dec 31, 2025 | -491,000.00 |
| Sep 30, 2025 | 544,000.00 |
| Sep 30, 2025 | 544,000.00 |
| Jun 30, 2025 | -131,000.00 |
| Jun 30, 2025 | -131,000.00 |
| Mar 31, 2025 | 138,000.00 |
| Mar 31, 2025 | 138,000.00 |
| Dec 31, 2024 | -463,000.00 |
| Dec 31, 2024 | -463,000.00 |
| Sep 30, 2024 | 723,000.00 |
| Sep 30, 2024 | 723,000.00 |
| Jun 30, 2024 | 91,000.00 |
| Jun 30, 2024 | 91,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | -60,000.00 |
| Dec 31, 2023 | -60,000.00 |
| Sep 30, 2023 | 265,000.00 |
| Sep 30, 2023 | 265,000.00 |
| Jun 30, 2023 | -585,000.00 |
| Jun 30, 2023 | -585,000.00 |
| Mar 31, 2023 | 629,000.00 |
| Mar 31, 2023 | 629,000.00 |
| Dec 31, 2022 | 20.37 Mn |
| Dec 31, 2022 | 20.37 Mn |
| Sep 30, 2022 | -2.80 Mn |
| Sep 30, 2022 | -2.80 Mn |
| Jun 30, 2022 | -2.22 Mn |
| Jun 30, 2022 | -2.22 Mn |
| Mar 31, 2022 | 5.28 Mn |
| Mar 31, 2022 | 5.28 Mn |
| Dec 31, 2021 | -8.47 Mn |
| Dec 31, 2021 | -8.47 Mn |
| Sep 30, 2021 | 10.61 Mn |
| Sep 30, 2021 | 10.61 Mn |
| Jun 30, 2021 | 1.50 Mn |
| Jun 30, 2021 | 1.50 Mn |
| Mar 31, 2021 | 452,000.00 |
| Mar 31, 2021 | 452,000.00 |
| Dec 31, 2020 | -1.22 Mn |
| Dec 31, 2020 | -1.22 Mn |
| Sep 30, 2020 | 162,000.00 |
| Sep 30, 2020 | 162,000.00 |